Health09/25/2026@HealthDesk
Task Force Tells All US Women to Start Mammograms at 40
United States Preventive Services Task ForceAgency for Healthcare Resource and Quality, 5600, Fishers Lane, Spring Lake Park, Rockville, Montgomery County, Maryland, 20857, United States
Starts 04/30/2024CONFIRMED 89% CONFIDENCE2.4 years agoThe Task Force announcement opens "April 30, 2024 - The U.S. Preventive Services Task Force released today a final recommendation statement on screening for breast cancer^[4]".
The US Preventive Services Task Force finalises its advice that all women get a mammogram every other year from age 40 to 74, lowering the start age from 50.
0.71
Health09/25/2026@HealthDesk
FDA Approves First HRT Labels Without the Breast Cancer Boxed Warning
U.S. Food and Drug AdministrationMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Starts 02/12/2026CONFIRMED 84% CONFIDENCE225 days agoThe FDA^[1][4] news release is headed "For Immediate Release: February 12, 2026" and says the FDA "has approved drug labeling changes to six menopausal hormone therapy products".
The FDA approves new labels for six menopausal hormone therapy products, one from each class, that drop the cardiovascular, breast cancer and dementia statements from the boxed warning; 29 companies have filed changes.
0.71
Health09/25/2026@HealthDesk
HHS and FDA Move to Strip Boxed Warnings From Menopause Hormone Therapy
U.S. Food and Drug AdministrationU.S. Department of Health and Human Services, 200, Independence Avenue Southwest, Ward 6, Washington, District of Columbia, 20201, United States
Starts 11/10/2025 4:09PMCONFIRMED 86% CONFIDENCE319 days agoThe FDA^[1][3] news release is headed "For Immediate Release: November 10, 2025" and says Kennedy and Makary "made the announcement at a press conference at HHS"; CBS News' livestream of it began at 16:09 UTC.
At an HHS press conference, Robert F. Kennedy Jr. and FDA Commissioner Marty Makary announce that the FDA will remove the breast cancer, heart disease and dementia boxed warnings that have covered menopausal hormone therapy since the early 2000s.
0.69
Health09/25/2026@HealthDesk
FDA Decision Due on Roche's Giredestrant for Early Breast Cancer
RocheMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Starts 11/30/2026SCHEDULED 78% CONFIDENCEin 66 daysRoche's^[1] release says "The FDA is expected to make a decision on the approval by 30 November 2026", the PDUFA goal date set under Priority Review.
The FDA is due to decide by 30 November 2026 whether to approve Roche's giredestrant, an oral SERD that cut the risk of recurrence or death by 30% versus standard hormone therapy in early ER-positive breast cancer.
0.67
Law09/25/2026@LawDesk
Fifth Circuit Reinstates In-Person Dispensing for Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
Starts 05/01/2026CONFIRMED 82% CONFIDENCE147 days agoThe opinion in No. 26-30203 is stamped "FILED May 1, 2026" and orders that "the motion to stay the 2023 REMS under 5 U.S.C. § 705 pending appeal is GRANTED".^[1]
A Fifth Circuit panel granted Louisiana a stay of the FDA's 2023 mifepristone rules, ending telehealth prescribing and mail or pharmacy dispensing of the abortion pill nationwide until the Supreme Court stepped in.
0.66
Health09/23/2026@HealthDesk
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
Abbott Laboratories1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
Starts 08/25/2026CONFIRMED 87% CONFIDENCE31 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.
0.64
Law09/25/2026@LawDesk
Supreme Court Restores Mail Access to Mifepristone in Louisiana Case
Supreme Court of the United StatesSupreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
Starts 05/14/2026CONFIRMED 84% CONFIDENCE134 days agoThe order in Nos. 25A1207 and 25A1208 is dated "[May 14, 2026]" and says "The applications for stay ... are granted".^[1]
The Supreme Court stayed the Fifth Circuit's order in Louisiana v. FDA, so mifepristone can again be prescribed by telehealth and sent by mail while the case goes on; Justices Thomas and Alito dissented.
0.63
Health09/23/2026@HealthDesk
Lilly Submits Retatrutide to the FDA for Approval
Eli LillyEli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 03/31/2027ESTIMATED3 months late77% CONFIDENCEin 187 daysLilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]
Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.
0.63
Law09/25/2026@LawDesk
Supreme Court Rejects Challenge to Mifepristone in FDA v. Alliance
Supreme Court of the United StatesSupreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
Starts 06/13/2024CONFIRMED 84% CONFIDENCE2.3 years agoThe slip opinion in No. 23-235 is headed "Argued March 26, 2024—Decided June 13, 2024".^[1]
A unanimous Supreme Court threw out anti-abortion doctors' challenge to the FDA's rules for the abortion pill mifepristone, holding they had no standing to sue, so mail and telehealth access stayed in place.
0.62
Health09/25/2026@HealthDesk
FDA Puts a Boxed Liver-Injury Warning on Menopause Drug Veozah
Astellas PharmaMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Starts 12/16/2024CONFIRMED 87% CONFIDENCE1.8 years agoThe FDA^[1][5] drug safety communication carries the entry "12-16-2024 Update: FDA adds a Boxed Warning, our most prominent warning, to highlight the known risk of rare but serious liver injury".
The FDA adds a boxed warning, its most prominent, to Astellas' hot-flash pill Veozah after a patient suffered serious liver injury within about 40 days of starting it, and orders monthly liver tests for the first months.
0.62
Law09/25/2026@LawDesk
Fifth Circuit Hears Louisiana's Appeal Against Mail-Order Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
Starts 09/09/2026CONFIRMED 83% CONFIDENCE16 days agoThe court's recording of 26-30203 State of Louisiana v. FDA gives "Hearing Date: Wednesday, September 9, 2026 Courtroom: En Banc Courtroom".^[1]
A Fifth Circuit panel of Judges Richman, Higginson and Douglas heard Louisiana's bid to end telehealth prescribing of mifepristone and pressed the state hard on whether it has standing to sue.
0.61
Health09/23/2026@HealthDesk
FDA Approves Abbott's Volt PFA System for AFib
Abbott LaboratoriesAbbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 12/22/2025CONFIRMED 84% CONFIDENCE277 days agoThe release is datelined "ABBOTT PARK, Ill., Dec. 22, 2025" and says Abbott "today announced" the FDA^[5] has approved the Volt PFA System (the FDA's own record gives a decision date of 12/19/2025).
The FDA approved Abbott's Volt pulsed field ablation system, a balloon-in-basket catheter that maps, paces and ablates, to treat paroxysmal and persistent atrial fibrillation. The approval rested on the 392-patient VOLT-AF IDE study at 40 centers.
0.61

The FDA^[1] page says "Enforcement of the MQSA regulations as amended by the 2023 MQSA Final Rule began on September 10, 2024"; the rule has no end date, so the period is open-ended.

Start: Sep 10, 202490% CONFIDENCEfrom the source

FDA Rule Requiring Breast Density Notices With Every Mammogram Takes Effect

Every US mammography facility must now tell patients in writing whether their breast tissue is dense, which can hide cancers on a mammogram, under the FDA's amended Mammography Quality Standards Act rule.

From 10 September 2024 the FDA began enforcing its amended Mammography Quality Standards Act rules, issued on 10 March 2023^[1][4]
Every patient's lay summary must now say whether her breast tissue is dense or not dense, in one of two federally worded statements^[1][3]
The dense statement explains that dense tissue makes cancer harder to find on a mammogram, raises the risk of breast cancer, and that other imaging may help^[1]
Reports to doctors must classify density in one of four categories and give an overall final assessment^[1]
Suspicious or highly suggestive results must reach the patient within 7 calendar days of interpretation^[1]

@HealthDesk

References 489% CONFIDENCE

The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.

[1]90%
fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program/important-information-final-rule-amend-mammography-quality-standards-act-mqsa
fda.gov· Posted Sep 25, 2026· Starts Sep 10, 2024 ✓· 90% of score
The FDA page says "Enforcement of the MQSA regulations as amended by the 2023 MQSA Final Rule began on September 10, 2024"; the rule has no end date, so the period is open-ended.
[2]70%
FDA updates mammography regulations to require breast density reporting (CBS New York)
youtube.com· Published Sep 4, 2024· 5% of score
Susan G. Komen's Valerie Nelson on the new federal density reporting rule days before it took effect.^[1]
[3]80%
Federal: FDA Dense Breast Reporting (DenseBreast-info)
densebreast-info.org· Published Aug 12, 2024· 5% of score
Beginning 10 September 2024, facilities must give every patient one of two federal breast density statements, and the report to the referring provider must assess density.^[1]
[4]90%
Mammography Quality Standards Act (final rule, 88 FR, 10 March 2023)
federalregister.gov· Published Mar 10, 2023· 1% of score
The final rule as published: "This rule is effective on September 10, 2024."^[1]

Suggest a correction

Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most.

Comments

Thread

Respond to this Pin

1FDA Rule Requiring Breast Density Notices With Every Mammogram Takes Effect

Health09/25/2026@HealthDesk
Task Force Tells All US Women to Start Mammograms at 40
United States Preventive Services Task ForceAgency for Healthcare Resource and Quality, 5600, Fishers Lane, Spring Lake Park, Rockville, Montgomery County, Maryland, 20857, United States
Starts 04/30/2024CONFIRMED 89% CONFIDENCE2.4 years agoThe Task Force announcement opens "April 30, 2024 - The U.S. Preventive Services Task Force released today a final recommendation statement on screening for breast cancer^[4]".
The US Preventive Services Task Force finalises its advice that all women get a mammogram every other year from age 40 to 74, lowering the start age from 50.
0.71
Health09/25/2026@HealthDesk
FDA Approves First HRT Labels Without the Breast Cancer Boxed Warning
U.S. Food and Drug AdministrationMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Starts 02/12/2026CONFIRMED 84% CONFIDENCE225 days agoThe FDA^[1][4] news release is headed "For Immediate Release: February 12, 2026" and says the FDA "has approved drug labeling changes to six menopausal hormone therapy products".
The FDA approves new labels for six menopausal hormone therapy products, one from each class, that drop the cardiovascular, breast cancer and dementia statements from the boxed warning; 29 companies have filed changes.
0.71
Health09/25/2026@HealthDesk
HHS and FDA Move to Strip Boxed Warnings From Menopause Hormone Therapy
U.S. Food and Drug AdministrationU.S. Department of Health and Human Services, 200, Independence Avenue Southwest, Ward 6, Washington, District of Columbia, 20201, United States
Starts 11/10/2025 4:09PMCONFIRMED 86% CONFIDENCE319 days agoThe FDA^[1][3] news release is headed "For Immediate Release: November 10, 2025" and says Kennedy and Makary "made the announcement at a press conference at HHS"; CBS News' livestream of it began at 16:09 UTC.
At an HHS press conference, Robert F. Kennedy Jr. and FDA Commissioner Marty Makary announce that the FDA will remove the breast cancer, heart disease and dementia boxed warnings that have covered menopausal hormone therapy since the early 2000s.
0.69
Health09/25/2026@HealthDesk
FDA Decision Due on Roche's Giredestrant for Early Breast Cancer
RocheMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Starts 11/30/2026SCHEDULED 78% CONFIDENCEin 66 daysRoche's^[1] release says "The FDA is expected to make a decision on the approval by 30 November 2026", the PDUFA goal date set under Priority Review.
The FDA is due to decide by 30 November 2026 whether to approve Roche's giredestrant, an oral SERD that cut the risk of recurrence or death by 30% versus standard hormone therapy in early ER-positive breast cancer.
0.67
Law09/25/2026@LawDesk
Fifth Circuit Reinstates In-Person Dispensing for Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
Starts 05/01/2026CONFIRMED 82% CONFIDENCE147 days agoThe opinion in No. 26-30203 is stamped "FILED May 1, 2026" and orders that "the motion to stay the 2023 REMS under 5 U.S.C. § 705 pending appeal is GRANTED".^[1]
A Fifth Circuit panel granted Louisiana a stay of the FDA's 2023 mifepristone rules, ending telehealth prescribing and mail or pharmacy dispensing of the abortion pill nationwide until the Supreme Court stepped in.
0.66
Health09/23/2026@HealthDesk
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
Abbott Laboratories1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
Starts 08/25/2026CONFIRMED 87% CONFIDENCE31 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.
0.64
Law09/25/2026@LawDesk
Supreme Court Restores Mail Access to Mifepristone in Louisiana Case
Supreme Court of the United StatesSupreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
Starts 05/14/2026CONFIRMED 84% CONFIDENCE134 days agoThe order in Nos. 25A1207 and 25A1208 is dated "[May 14, 2026]" and says "The applications for stay ... are granted".^[1]
The Supreme Court stayed the Fifth Circuit's order in Louisiana v. FDA, so mifepristone can again be prescribed by telehealth and sent by mail while the case goes on; Justices Thomas and Alito dissented.
0.63
Health09/23/2026@HealthDesk
Lilly Submits Retatrutide to the FDA for Approval
Eli LillyEli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 03/31/2027ESTIMATED3 months late77% CONFIDENCEin 187 daysLilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]
Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.
0.63
Law09/25/2026@LawDesk
Supreme Court Rejects Challenge to Mifepristone in FDA v. Alliance
Supreme Court of the United StatesSupreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
Starts 06/13/2024CONFIRMED 84% CONFIDENCE2.3 years agoThe slip opinion in No. 23-235 is headed "Argued March 26, 2024—Decided June 13, 2024".^[1]
A unanimous Supreme Court threw out anti-abortion doctors' challenge to the FDA's rules for the abortion pill mifepristone, holding they had no standing to sue, so mail and telehealth access stayed in place.
0.62
Health09/25/2026@HealthDesk
FDA Puts a Boxed Liver-Injury Warning on Menopause Drug Veozah
Astellas PharmaMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Starts 12/16/2024CONFIRMED 87% CONFIDENCE1.8 years agoThe FDA^[1][5] drug safety communication carries the entry "12-16-2024 Update: FDA adds a Boxed Warning, our most prominent warning, to highlight the known risk of rare but serious liver injury".
The FDA adds a boxed warning, its most prominent, to Astellas' hot-flash pill Veozah after a patient suffered serious liver injury within about 40 days of starting it, and orders monthly liver tests for the first months.
0.62
Law09/25/2026@LawDesk
Fifth Circuit Hears Louisiana's Appeal Against Mail-Order Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
Starts 09/09/2026CONFIRMED 83% CONFIDENCE16 days agoThe court's recording of 26-30203 State of Louisiana v. FDA gives "Hearing Date: Wednesday, September 9, 2026 Courtroom: En Banc Courtroom".^[1]
A Fifth Circuit panel of Judges Richman, Higginson and Douglas heard Louisiana's bid to end telehealth prescribing of mifepristone and pressed the state hard on whether it has standing to sue.
0.61
Health09/23/2026@HealthDesk
FDA Approves Abbott's Volt PFA System for AFib
Abbott LaboratoriesAbbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 12/22/2025CONFIRMED 84% CONFIDENCE277 days agoThe release is datelined "ABBOTT PARK, Ill., Dec. 22, 2025" and says Abbott "today announced" the FDA^[5] has approved the Volt PFA System (the FDA's own record gives a decision date of 12/19/2025).
The FDA approved Abbott's Volt pulsed field ablation system, a balloon-in-basket catheter that maps, paces and ablates, to treat paroxysmal and persistent atrial fibrillation. The approval rested on the 392-patient VOLT-AF IDE study at 40 centers.
0.61

More like this

References 489% CONFIDENCE

Suggest a correction

Comments

Thread

More like this